Inovio doses first participant in phase 2 trial for its dna vaccine against middle east respiratory syndrome (mers), a coronavirus disease

Plymouth meeting, pa., aug. 4, 2021 /prnewswire/ -- inovio (nasdaq: ino), a biotechnology company bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that the company has dosed the first phase 2 trial subject in its quest to develop the first vaccine against the middle east respiratory syndrome (mers).
INO Ratings Summary
INO Quant Ranking